Traduction de «novartis is also cooperating with an inquiry » (Néerlandais → Français) :

Novartis is also cooperating with an inquiry by the EDPA regarding similar allegations of potential off-label marketing and promotion and payments to healthcare providers in connection with five other products: Diovan, Exforge, Sandostatin, Tekturna and Zelnorm.
Novartis coopère également avec l’EPDA dans le cadre d’une enquête concernant des accusations similaires en relation avec cinq autres produits: Diovan, Exforge, Sandostatine, Tekturna et Zelnorm.

The Company is responding to the requests and will cooperate with the inquiry.
La société répond à ces requêtes et coopèrera à l’enquête.

At this time, Novartis is unable to assess with any reasonable certainty the likely outcomes, which may be material, of the discussions regarding Trileptal or the inquiry regarding the other five products.
A ce stade, Novartis est dans l’impossibilité d’évaluer, avec un degré de certitude raisonnable, l’issue probable, susceptible d’être matérielle, des discussions concernant Trileptal ou les investigations sur les cinq autres produits.

Novartis is cooperating with parallel civil and criminal investigations of the US Attorney’s Office into allegations of potential off-label marketing and promotion of the epilepsy therapy Trileptal as well as certain payments made to healthcare providers in connection with this medicine.
Novartis coopère aux investigations civiles et criminelles que ce bureau mène en parallèle au sujet d’accusations de promotion de Trileptal, un traitement contre l’épilepsie, pour des indications pour lesquelles ce produit n’a pas été autorisé, et de certains paiements à des prestataires de soins de santé en lien avec ce médicament.

Novartis is cooperating with parallel civil and criminal investigations of the US Attorney’s Office into allegations of potential off-label promotion of the epilepsy therapy Trileptal.
Novartis coopère aux investigations civiles et criminelles que ce bureau mène en parallèle au sujet d’accusations de promotion de Trileptal, un traitement contre l’épilepsie, pour des indications pour lesquelles ce produit n’a pas été autorisé.

Novartis is cooperating with parallel civil and criminal investigations of the US Attorney’s Office into allegations of potential off-label promotion of Trileptal.
Novartis coopère aux investigations civiles et criminelles que ce bureau mène en parallèle au sujet d’accusations de promotion de Trileptal pour des indications pour lesquelles ce produit n’a pas été autorisé.

Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of
Considerable attention was focused in 2007 on increased cooperation on the part of the FAMHP with the ethics committees, with the following results: ●● An interactive website with a web application that makes possible the “simple” management of communication actions between the different ethics committees, the FAMHP, the sponsors and researchers, and also monitors the different stages in the evaluation of each application by the ethics committees ●● Systematic consultation for the more complex scientific applications ●● Further optimisation of the functioning of

NPC has also been cooperating with an investigation by the EDPA regarding potential off-label marketing and promotion as well as payments made to healthcare providers in connection with five other products, i.e. Diovan, Exforge, Sandostatin, Tekturna and Zelnorm (Five Products).
NPC a également coopéré à une enquête menée par l’EDPA au sujet d’accusations de promotion pour des indications pour lesquelles des produits n’ont pas été autorisés, et de paiements à des prestataires de soins de santé en lien avec cinq autres produits: Diovan, Exforge, Sandostatine, Tekturna et Zelnorm.

Direct cooperation with dossier administrators who monitor the central procedure (CP) is also required.
Direct cooperation with dossier administrators who monitor the central procedure (CP) is also required.